SNDX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Munich

syndax pharmaceuticals inc (SNDX) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SYNDAX PHARMACEUTICALS INC (SNDX)
\

Related News

No related news articles were found.

syndax pharmaceuticals inc (SNDX) Related Businessweek News

No Related Businessweek News Found

syndax pharmaceuticals inc (SNDX) Details

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company’s lead product candidates include entinostat, which is in Phase III clinical trials for the treatment of advanced hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer; and SNDX-5613 inhibitor that targets the binding interaction of Menin with mixed lineage leukemia-rearranged and acute myeloid leukemia with a mutated nucleophosmin 1. It also develops entinostat with Keytruda (pembrolizumab) in a Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and melanoma or microsatellite stable colorectal carcinoma; with Tecentriq (atezolizumab) in a Phase Ib/II clinical trials to treat patients with triple-negative breast cancer, and HR+ and HER2- metastatic breast cancer; and with Bavencio (avelumab) in a Phase Ib/II clinical trials for the treatment of ovarian cancer. In addition, the company develops SNDX-6352, a monoclonal antibody that blocks the colony stimulating factor 1 that is in Phase I dose escalation trial in patients with chronic graft versus host disease; and as a monotherapy and in combination with Imfinzi (durvalumab), which is in Phase I/Ib dose trials for the treatment of solid tumors. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH; Genentech, Inc.; Merck KGaA and Pfizer; and AstraZeneca plc. It also has collaborative research and development agreement with National Cancer Institute; clinical trial agreement with Eastern Cooperative Oncology Group; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts.

38 Employees
Last Reported Date: 03/7/19
Founded in 2005

syndax pharmaceuticals inc (SNDX) Top Compensated Officers

CEO & Director
Total Annual Compensation: $816.7K
President & COO
Total Annual Compensation: $730.9K
CFO & Treasurer
Total Annual Compensation: $13.0K
Chief Medical Officer & Senior VP
Total Annual Compensation: $577.1K
Compensation as of Fiscal Year 2018.
syndax pharmaceuticals inc
Syndax Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019

Syndax Pharmaceuticals, Inc. announced earnings results for the first quarter ended March 31, 2019. For the first quarter, the company announced operating income was USD 14.811 million compared to USD 19.751 million a year ago. Net loss was USD 14.302 million compared to USD 19.398 million a year ago. Basic loss per share was USD 0.53 compared to USD 0.79 a year ago.

Syndax Pharmaceuticals, Inc. to Report Q1, 2019 Results on May 06, 2019

Syndax Pharmaceuticals, Inc. announced that they will report Q1, 2019 results at 4:30 PM, US Eastern Standard Time on May 06, 2019

Syndax Pharmaceuticals, Inc., Q1 2019 Earnings Call, May 06, 2019

Syndax Pharmaceuticals, Inc., Q1 2019 Earnings Call, May 06, 2019

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

SNDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SNDX.
View Industry Companies
 

Industry Analysis

SNDX

Industry Average

Valuation SNDX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 154.6x
Price/Book 3.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 91.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact SYNDAX PHARMACEUTICALS INC, please visit www.syndax.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.